Bionovo initiates enrollment in Menerba Stage 1 medical trial for menopausal hot flushes Bionovo, Inc. , a pharmaceutical company centered on the discovery and advancement of effective and safe remedies for women’s health insurance and tumor, today announced that enrollment provides started for the Stage 1 clinical trial screening the security of two dosages of Menerba in postmenopausal ladies for the treating menopausal hot flushes , referred to as menopausal sizzling hot flashes also. This Stage 1, open-label, randomized, medical trial of Menerba will be conducted at three scientific sites in Northern California get more information .
Experts is now able to easily, safely and price effectively transport huge volumes of bloodstream samples from stage of treatment collection sites to the laboratory for subsequent evaluation without threat of sample quality diminishing. Space temperatures based biostability reagents provide a very economical, eco-friendly remedy to biological sample preservation, storage and transport, offering a paradigm change from traditional cold-freezing strategies thereby. DNAgard Bloodstream shall begin shipping and delivery to clients starting on Sept 30, 2010. After long-term storage space, high yield and quality DNA could be extracted and the purified sample is preparing to make use of for all downstream evaluation such as for example genotyping and entire genome DNA sequencing.